Claims
- 1. Substituted pyrrolidinones of the formula ##STR50## wherein R.sub.1 is a phenyl group which can be mono- or di-substituted by methyl, methoxy, fluorine, chlorine, bromine or trifluoromethyl, or a pyridyl group;
- R.sub.2 is hydrogen or a straight-chained or branched alkyl group with 1-4 carbon atoms;
- R.sub.3 and R.sub.4 together with the nitrogen atom form a morpholine ring, which ring can be substituted by 1 or 2 methyl groups;
- as well as physiologically acceptable acid addition salts thereof.
- 2. Pyrrolidinones according to claim 1 wherein R.sub.1 is a phenyl group and R.sub.2 is hydrogen.
- 3. Compounds in accordance with claims 1 or 2 in their optically active form.
- 4. A pharmaceutical composition for treating cerebral insufficiency comprising a pharmaceutically acceptable carrier and an effective amount of a compound in accordance with claims 1 or 2.
- 5. A method for treating conditions characterized by cerebral insufficiency or diminished cerebral performance which comprises administering, to a host requiring such treatment, a therapeutically effective amount of a compound in accordance with claims 1 or 2.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3420193 |
May 1984 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 738,152, filed May 24, 1985 now U.S. Pat. No. 4,670,456.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4369139 |
Kyburz et al. |
Jan 1983 |
|
4670436 |
Epps et al. |
Jun 1987 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
738152 |
May 1985 |
|